Pregnancy, epilepsy, and anticonvulsants by Steinhoff, Bernhard J
Fertile women with epilepsy 
Epilepsy and fertility in general
atients with epilepsy have been reported to suf-
fer from reduced fertility. The fertility rate ranges
between 33% and 100% of the expected model,
1-3 and is
reduced by 15% to 30% compared with healthy con-
trols.
3-5 In twins, the fertility rate of the affected twin
drops at the onset of the disease, compared with the
healthy twin.
6 In a controlled study,patients with epilepsy
reported less sexual intercourse,more frequent vaginis-
mus,and reduced sexual interest compared with healthy
controls.
6 Hyposexuality was reported in 34% of
patients,
7 whereas other reports did not confirm a clear
difference between patients with epilepsy and healthy
persons.
8,9 Both reduced and normal fertility rates were
reported for married women with epilepsy.
4,10 Overall,
50% of women with epilepsy suffer from dysfunctions
such as amenorrhea,oligomenorrhea,abnormally short-
ened or lengthened menstrual cycles,polycystic ovaries
(PCO) or the polycystic ovary syndrome (PCOS).
11-16
63
Pharmacological aspects
P
Copyright © 2008 LLS SAS.  All rights reserved www.dialogues-cns.org
Pregnancy, epilepsy, and anticonvulsants
Bernhard J. Steinhoff, MD, PhD
Keywords: epilepsy; antiepileptic drug; fertility; interaction; pregnancy; delivery;
puerperium; teratogenicity 
Author affiliations: Director, Kork Epilepsy Center, Kehl-Kork, Germany 
Address for correspondence: Prof Dr Bernhard J. Steinhoff, Medical Director,
Epilepsiezentrum Kork, Landstrasse 1, 77694 Kehl-Kork, Germany 
(e-mail: bsteinhoff@epilepsiezentrum.de)
The majority of epileptic disorders are not self-limiting
over time, and therefore require a long-lasting and often
even lifelong antiepileptic drug (AED) treatment. In
women with epilepsy, the influence of their disease on the
possibility and course of pregnancies, as well as the poten-
tial impact of the AED treatment on mother and child, are
crucial questions. 
This review addresses the clinically relevant knowledge
concerning the impact of the disease itself and the AED
treatment on fertility, pregnancy, delivery, the postpartum
period, and teratogenicity. Some of the new AEDs appear
to have a favorable profile due to a lack of clinically rel-
evant interactions and promising teratogenic profiles.
However, the finding of decreases in lamotrigine serum
concentrations during hormonal contraception and preg-
nancy is an instructive example, showing that ongoing
studies are urgently needed to further investigate still-
unanswered questions. Several prospective multinational
surveys are currently being performed, and should add
essential information in this context.
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The fertility rate in epileptic women may be influenced
by the underlying epilepsy syndrome. In women with
temporal lobe epilepsies (TLE) abnormal findings with
a possible impact on fertility are especially common:
Abnormal menstrual cycles occur in 50% of women with
TLE.
15The rate of anovulatory cycles was 25% to 30%
compared with a rate of 8% to 10% in healthy controls,
17
and 14% to 20%,compared with 0% of women with gen-
eralized epilepsy syndromes and 8% of healthy controls.
18
Data on patients with generalized epilepsy syndromes
are somewhat conflicting: According to Webber and
coworkers,
3 women with generalized epilepsies have the
same fertility rates as women without epileptic seizures,
independent of concomitant antiepileptic drug (AED)
treatment,whereas a more recent article reported that
anovulatory cycles occurred more frequently in this
patient group (with valproic acid [VPA] treatment as an
additional risk factor) than in patients with partial
epilepsy syndromes.
1
The functional circuits between temporal lobe structures
and the hypothalamus may be responsible for the
reduced fertility of women with temporal lobe epilep-
sies.
19 Ongoing epileptic activity from the temporal lobe
has an influence on the hypothalamic-hypophyseal axis
through the tight connections between the limbic system
and hypothalamic nuclei that are responsible for the reg-
ulation, production, and secretion of gonadotropin-
releasing hormone (GnRH).Ictal activity in the mesial
temporal lobe leads to either a PCO by the increase in
GnRH, with a consecutive rise in luteinizing hormone
(LH) and fall in follicle-stimulating hormone (FSH),or
conversely induces a fall in GnRH with a fall in LH and
rise in FSH,thus leading to hypogonadotropic hypogo-
nadism.Both developments cause a decrease in proges-
terone.
20 PCO has been associated with left-sided,hypog-
onadotropic hypogonadism with right-sided TLE.
16,21
Successful resective TLE surgery led to a restoration of
reproductive functions,
22 which strongly suggests the
involvement of TLE.
Possible impact of antiepileptic drugs on fertility
It is methodically difficult to assess the potential impact
of AEDs on fertility.Although chronic AED treatment
has been claimed to cause a variety of long-term side
effects, unequivocal data on the impact on fertility in
female patients are rare.
In particular, AEDs that cause enzyme induction (see
below) are potential candidates for a clinically relevant
influence on sexual hormone levels that might contribute
to fertility problems.Nevertheless,a closer look at the lit-
erature does not reveal consistent findings
2: 33% of
patients treated with carbamazepine (CBZ) suffered from
reduced sexual interest.
23VPA increased the risk of anovu-
latory cycles in another study.
1 In women receiving AED
polytherapy anovulatory cycles were increased,but not
significantly more often than in patients on monotherapy.
18
Bauer claims that abnormal menstrual cycles are more
probably caused by the AED treatment than by the dis-
ease itself.
24
In 1975,Schmitz and coworkers
25 reported increased FSH
and LH levels with phenytoin (PHT) treatment,whereas
others did not confirm this finding,either with PHT or
CBZ.
26
In healthy volunteers, CBZ or PHT dosing for 1 week
caused rises in prolactin serum levels.
27 Elevated prolactin
levels were also found in women on long-term AED ther-
apy.
28 Others described that CBZ had no impact on pro-
lactin and FSH,but lowered LH levels.
29 Finally,another
report did not confirm any differences concerning basal
gonadotropin and prolactin between patients receiving
CBZ,VPA,phenobarbitol (PB),and healthy controls.
30
A study in girls and young adults with epilepsy who were
treated with VPA reported significantly elevated testos-
terone levels and hyperandrogenism at a rate of 57%.
31
With lamotrigine (LTG) no negative influence on the
sexual hormone metabolism was found,
32 which may also
be hypothesized for other new AEDs without a clinically
relevant interaction profile.
33 In particular,the potential
role of VPA for the risk of obesity,impaired insulin bal-
ance,and or PCO and PCOS has been actively discussed.
This crucial question of the treatment with AEDs and
fertility will be addressed in the following section.
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Selected abbreviations and acronyms
AED antiepileptic drug
CBZ carbamazepine
LTG lamotrigine
OXC oxcarbazepine
PB phenobarbitol
PCOS polycystic ovary syndrome
PHT phenytoin
PRM primidone
VPA valproic acidObesity, PCO, PCOS, and antiepileptic drugs
Obesity is one of the most common adverse effects seen
with long-term AED treatment,and has been reported for
almost every AED.
33Among the first-line AEDs,VPA is
the main risk substance for obesity.
34,35,36According to the
literature,the incidence of obesity on VPA varies widely,
and ranges between 8% and 59%.
37 Female patients who
suffered from weight gain while on VPA had increased
insulin levels and insulin resistance,
38 which was confirmed
by the comparison with patients receiving CBZ or LTG.
39
Others reported normal insulin levels with VPA,CBZ,and
oxcarbazepine (OXC) but still confirmed the almost spe-
cific weight gain on VPA.
40 This weight gain was com-
pletely reversible 12 months after replacing VPA by LTG,
as were hyperinsulinism,increased serum testosterone,and
abnormally high body mass index.
41
Obesity due to metabolic effects of VPA has become a
major subject of recent research,since it was hypothe-
sized that this metabolic development may induce
PCOS,
41 which is defined by the coincidence of oligo- or
amenorrhea, hyperandrogenism, and the ultrasound
detection of polycystic ovaries.
16The most relevant find-
ings in PCOS are shown in Table I.
Whether or not this is correct and specific for VPA is still
a matter of controversy.
33 Other groups did not find rel-
evant differences between PCOS and VPA,CBZ,PB,the
total population,or untreated epilepsy patients.
30,42
It has to be considered that the epilepsy itself may facil-
itate the development of PCOS by the metabolic changes
mentioned above.A pilot study addressing this aspect
reported that 25% of the investigated female patients
with epilepsy suffered from PCOS, 80% of whom had
not received AED therapy.
43 In another study,one third
of the patients with PCOS were not on medication.
44
Oral hormonal contraception
Impact of AEDs on oral hormonal contraception
The oral application of sexual hormones is the major
method of contraception.Liver enzyme-inducing AEDs
reduce the efficacy of oral contraceptives.
24,45 It was esti-
mated that the rate of unintentional pregnancies in spite
of hormonal contraception was five to 25 times higher
if enzyme-inducing AEDs were used.
46,47 Among the
AEDs that were reported to reduce the efficacy of hor-
monal contraceptives are CBZ,ethosuximide (ESM),fel-
bamate (FBM),LTG,OXC,PB,PHT,primidone (PRM),
and topiramate (TPM), with the latter AED showing
reduced effect only on estrogen levels and at daily
dosages above 200 mg.
20,24,48,49The negative impact of ESM
has been questioned elsewhere,
50 and the influence of
AEDs that are not potent enzyme inducers,such as TPM
or LTG, may result from different mechanisms, since
TPM induces the estrogenic and LTG the gestagenic
components.
51 It is unclear to what extent these findings
are clinically relevant,since unintentional pregnancies
were hitherto not reported in women who were treated
with LTG and continued oral hormonal contraception.
24
AEDs that induce the cytochrome P450 enzymes reduce
the efficacy of oral contraceptives markedly.Under the
influence of CBZ the levels of norethindrone and ethinyl
estradiol drop by 58% and 42%, respectively,
48 OXC
decreases the levels of ethinyl estradiol and lev-
onorgestrel if a daily dosage of 1200 mg is given.
52,53 Other
enzyme inducers such as PB,PHT,or PRM also unequiv-
ocally influence the metabolism of oral contraceptives so
markedly that one cannot expect an acceptable contra-
ceptive effect.
20,24,49,51 In a survey among neurologists and
obstetricians,27% of the former and 21% of the latter
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Clinical findings Endocrinological, metabolic, and ultrasound findings
Irregular menstrual cycles Polycystic ovaries
Amenorrhea Increased LH levels
Impaired fertility Increased LH:FSH ratio
Body hair and/or alopecia Increased androgen levels—testosterone, 
Acne androstendion
Obesity (dehydroepiandrosteronsulphate)
Abnormal lipid profiles
Insulin resistance
Table I. Most relevant findings in polycystic ovary syndrome; main features are displayed in bold letters.
24 LH, luteinizing hormone; FSH, follicle-stim-
ulating hormonegroup reported failures of oral contraception in women
taking AEDs.Surprisingly,in the very same survey,only
4% of the neurologists and 0% of the obstetricians knew
the potential impact of the six most common AEDs on
hormonal contraception.
54AEDs that supposedly do not
affect hormonal contraception are VPA, gabapentin
(GBP), levetiracetam (LEV), pregabaline (PGB),
tiagabine (TGB), vigabatrin (VGB), and zonisamide
(ZNS).
20,24,49,51 One has to consider that the extent of this
impact and the quality of the individual trial on the
AEDs mentioned above vary widely.
20
If oral hormonal contraception is the method of choice
for a patient who is treated with enzyme-inducing AEDs,
it is strongly recommended that preparations containing
more than 50 µg of estrogen be considered.
55 If intermit-
tent breakthrough bleeds occur, dosage should be
increased to 75 to 100 µg.
56 Since the number of break-
through bleeds and contraceptive failure differs signifi-
cantly between ethinyl estradiol dosages of 50 and 100
µg, it has even been proposed that the higher dose be
chosen from the start of the oral contraceptive treat-
ment.
50 Breakthrough bleeding does not always indicate
an unsatisfactory effect of the hormonal contraception.
Conversely,one has to take into consideration that the
suppression of breakthrough bleeds does not necessarily
reflect a sufficient contraceptive effect.
24
Another,though less important,mechanism that leads to
reduced efficacy of oral contraceptives is the reduction
in the free progesterone serum level that was described
for PB.
57
Impact of hormonal contraception on epilepsy and AEDs
There is no evidence for an impact of hormonal contra-
ception on the course of the epilepsy itself.
58,59
Over the last decade LTG was established as the major
medication in women with epilepsy who plan pregnan-
cies,due to its favorable safety profile,which will be dis-
cussed in a later section.If one considers this develop-
ment, it is surprising that it took several years until a
Danish group discovered the pronounced and clinically
relevant influence of oral hormonal contraceptives on
LTG.
60This was soon confirmed by other studies.
61-64 It has
been claimed that ethinyl estradiol, but not proges-
terones, are responsible for this reduction of the LTG
serum concentration.
65 In women on hormonal contra-
ception and LTG it is therefore reasonable to intensify
therapeutic drug monitoring and either to increase the
overall dosage to overcome seizure relapses during the
fall of the LTG serum concentration or to consider a con-
tinuous hormonal contraception without a placebo inter-
val.
Other methods of hormonal contraception
It has been suggested that the intramuscular application
of sex steroids that bypasses the hepatic first-pass metab-
olism may be a way to achieve a higher contraceptive
safety in patients on enzyme-inducing AEDs.However,
the data on this issue are controversial,and not sufficient.
It was shown that the efficacy of levonorgestrel is
reduced.
66,67 Data on medroxyprogesterone are not yet
available.
68 For safety reasons it was suggested that the
injection interval should be shortened from 12 to 10
weeks.
54 Whether or not this is really effective is not
absolutely sure.
25
Pregnancy—the mother's side
The course of epilepsy during pregnancy
There are no reliable predictors of the course of epilepsy
during pregnancy.
55 It has been reported that the risk of
seizure relapses corresponds to the seizure type,since an
increase in seizure frequency was significantly more often
found in patients with complex partial seizures than in
cases with generalized tonic-clonic and absence seizures.
69
However, this series of 79 pregnancies is certainly too
small to draw reliable conclusions.Similarly,the obser-
vation that a high seizure frequency prior to the preg-
nancy or the duration of the disease correlate with a
higher risk of increased seizure frequencies during preg-
nancy,
70 result from statistically unconvincing sample
sizes, and have been questioned somewhat.
71 Several
prospective pregnancy registries are being maintained in
order to generate more reliable data on the course of
pregnancy in patients with epilepsy and on the impact of
AEDs in epileptic and in nonepileptic women.In most
instances the course of epilepsy does not change during
pregnancy. According to several previously published
surveys,the seizure frequency remains stable in 50% to
85% of pregnancies of epileptic women.
16,24,49,71,72 The
assessment of 1956 pregnancies in 1882 patients revealed
that 58.3% remained seizure-free throughout the whole
period of pregnancy.
73 In another study,63% of patients
remained completely seizure-free.
74
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Electroencephalography (EEG) in women with epilepsy
prior to and during pregnancy did not reveal any increase
in epileptiform discharges.
75 Increases in the seizure fre-
quency appear in approximately 20% to 35%, and
decreases in 3% to 22%.
71 Data from the EURAP study
registry, which are prospectively collected, suggest
increases in seizures in 17.3% and decreases in 15.9%.
73
These rates are almost identical with data from Norway
that report 17% and 15%,respectively.
74 Status epilepti-
cus is a rare complication; it is thought to occur in less
than 1% of pregnancies.
24 More recent data collected in
almost 2000 pregnancies suggest an even lower rate (36
cases =0.02%).
73The latter study reported one stillbirth
as the only complication,and therefore indicated a lower
risk for mother and child than previously reported (mor-
tality rates of 31% for the mother and of 48% of the
child,
24 tenfold increased mortality in women with
epilepsy during pregnancy
76) which has since been con-
firmed by others.
74 Seizures were observed in 2.7% and
3.5%,respectively,during delivery.
73,74 In the Norwegian
study status epilepticus occurred in 1% with delivery.
74
The seizure risk is elevated ninefold on the delivery day;
seizure rates reached almost 20% in one study.
77 Others
report that seizures occur in 1% to 2% of patients dur-
ing the 24 perinatal hours.
78.79According to Bauer,
24 pre-
cipitating factors are:
1.Patients forget to continue their oral AED medication.
2.Sleep deprivation around the delivery, especially in
patients with idiopathic generalized epilepsies.
3.Intermittent hyperventilation, again especially in
patients with idiopathic generalized epilepsies.
4.The psychological stress during delivery.
An increase in seizures during the whole pregnancy
period is explained by various factors such as lack of
compliance because of fear of teratogenic AED effects,
increased levels of the theoretically proconvulsive estro-
gens,modified gastric motility,and an increase in nausea
and vomiting.
80 One other factor could be the influence
of the metabolic changes during pregnancy on the phar-
macokinetics of AEDs. Modified pharmacokinetics of
AEDs may result from altered protein binding or
increased hepatic metabolism.
80Among the new AEDs,
LTG has been advocated as a first-line drug due to its
promising teratogenic profile
81,82,83;this will be discussed
in detail later in this article. Since therefore numerous
patients are treated with LTG during pregnancy,it is clin-
ically relevant to know that LTG serum levels drop dur-
ing pregnancy due to a large increase in clearance,above
65%, and which may exceed 300%.
62,84,85 This was
explained by the increased metabolism of LTG.
85
Accordingly,seizure relapses under LTG monotherapy
during pregnancy and the necessity to increase the
dosage were observed.
62,73,84,85 Similarly, OXC had to be
increased during pregnancy due to seizure relapses.
73
Probably the underlying cause is similar,since reduced
serum concentrations of the active metabolite 10-hydrox-
ycarbazepine (MHD) were observed during the course
of pregnancy.
86,87Among the new AEDs it has been fur-
ther observed that a significant fall in LEV serum con-
centration may occur,
85 the clinical relevance of which is
still unclear.At least with LTG and OXC treatment ther-
apeutic drug monitoring may be helpful.
85 More system-
atic studies of the effects of pregnancy on the pharma-
cokinetics of new AEDs are urgently required.
85
Complications such as hyperemesis, vaginal bleeding,
pre-eclampsia,or peripartal problems such as early con-
tractions,weak contractions,or an increased caesarean
section rate occur twice as often as in healthy
women.
88,89,90 Finally,one should not ignore the fact that
during pregnancy other possibilities exist that may trig-
ger epileptic seizures, even in nonepileptic women. If
unexpected seizure relapses occur in patients with
epilepsy, one should therefore always consider and
exclude potential additional causative factors such as
cerebrovascular insults,cerebral processes,cerebral infec-
tions,toxic or metabolic causes,or eclampsia.
91
Risk factors for the child: possible 
complications during pregnancy, 
delivery, and the postnatal period
Possible complications during pregnancy
Most probably generalized tonic-clonic seizures during
pregnancy may threaten the child directly (trauma) and
indirectly (reduced placental perfusion.)
55 However,there
are no convincing data on these possible risks.We know
that spontaneous abortions that correspond with seizures
very rare.
71,92 However, the rate of stillbirths is higher
(5.1% vs 2.4%) in women who have suffered from
seizures during pregnancy than in seizure-free patients.
93
Complex partial seizures also temporarily influence the
heart rate of the child due to contractions of the uterus
and a resulting reduced fetal blood flow.
94
Preeclampsia,placental bleeding,and immature delivery
occur 1.5 to threefold more often in epileptic patientsthan in the general population.Perinatal mortality is ele-
vated by a factor of 1.2 to 2.
95 Abnormally low birth
weights are found 2.8-fold more frequently.Children of
women with epilepsy also have an elevated risk of low
APGAR scores and perinatal asphyxia.
90 Over one
decade perinatal mortality dropped continuously from
4.7% between 1977 and 1981 to 2.1% between 1987 and
1991.
55 The perinatal mortality rate in the German
EURAP register is 1.4%.
96
One important aspect of the perinatal period is the risk of
intracerebral bleeding in the infant.Therefore,it has been
suggested for some decades that during the last 4 weeks of
pregnancy the mother should be supplemented by vitamin
K in order to overcome coagulopathies of the child due to
the vitamin K deficiency that has been mostly attributed
to the impact of enzyme-inducing AEDs.
20,24,55 In addition,
every child is supplied with vitamin K to minimize the
bleeding risk. Recent data from a large cohort study in
Finland,
97 however,do not support the necessity of vitamin
K application:The authors followed 662 pregnancies of
women taking enzyme-inducing AEDs. They were not
given vitamin K,and no statistically significant difference
was found concerning the risk of intracerebral bleeding
compared with healthy controls.
Genetic epilepsy risk
If one excludes epilepsy syndromes with a very high
genetic preponderance,such as benign familial newborn
seizures,juvenile myoclonic epilepsy,tuberous sclerosis,
and others,
98 the general risk of suffering from epileptic
seizures during the first 20 years of life is 8.7% in case of
a maternal and 2.4% in case of a paternal epilepsy.
99
Idiopathic epilepsies are associated with an epilepsy risk
in the children of between 5% and 20%; this reaches
25% if both parents are affected.
24 Patients with epilepsy
should make use of the possibilities of human genetic
counseling in order to estimate the individual risk of
epilepsy in their children.
Postnatal period
After delivery one has to consider reducing AED dosage
again, if it has had to be reduced during pregnancy, to
avoid postnatal intoxication of the mother.There is no
general contraindication for breastfeeding.Since the chil-
dren were exposed to the AED of the mother during
pregnancy,breastfeeding may even help to avoid with-
drawal symptoms in the child,since almost all AEDs are
transported by breast milk.
24The concentrations range
widely and depend of the AED plasma protein bind-
ing.
24,71,100The most frequent problem with breastfeeding
may be sedation of the child, with consequent sucking
weakness.Among the new AEDs the milk/serum level is
0.6.
101 Nevertheless,in children therapeutic ranges of LTG
have been measured,due to the reduced metabolism of
the drug in newborns.
102 Since LTG is among the most
frequently used AEDs in pregnancy,
81,82,96,103 the behavior
of the child should be watched carefully.This is certainly
a general rule beyond pure LTG treatment.Although the
recommendations vary widely,
100 for the classical AEDs
there are no concerns about CBZ, PHT, and VPA.
104
Breastfeeding is also possible during the use of PB,PRM,
and benzodiazepines,although the rate of sedation and
sucking disturbances may be higher.
100,104,105 Close clinical
monitoring is recommended in the case of PB and etho-
suximide,which is highly concentrated in breast milk and
occasionally reaches the same levels as in the maternal
blood.
100 FBM is also considered to be required in order
to satisfactorily judge the suitability of new AEDs for
breastfeeding.
100,105
Teratogenicity
The risk of malformation is increased in children of
mothers with epilepsy. Most references report malfor-
mation rates that are two to three times higher than in
the normal population.
71,100,106-110 The maximum range
varies between a 1.25-fold and a fivefold elevated
risk.
111,112 One differentiates between minor and major
congenital abnormalities.There is almost no major mal-
formation that has not been mentioned in the context of
epilepsies and AED treatment. Heart malformations,
cleft lip and palate,skeletal deformities,diaphragmatic
hernias, malformations of the central nervous system,
gastrointestinal atresias,and urogenital malformations
have most commonly been reported.
100 Heart failure and
craniofacial clefts are the malformations with the high-
est incidence in children of women with epilepsy.
100 In
order to estimate the increased risk of malformations
accordingly, one has to keep in mind the spontaneous
malformation rates in the general population.Figures in
the literature vary from 0.4% to 6.4%.
113 Holmes et al
108
reported an incidence of 1.8%,according to other reports
it ranges between 2% and 3%.
71,114 Malformations in chil-
dren of women with epilepsy who did not take AEDs
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68during pregnancy are similar and range between 0% and
3.5% (in smaller cohorts than in the studies on the gen-
eral population).
108,109,115,116This suggests no epilepsy-spe-
cific additional risk.However,this is not necessarily true,
since the underlying epilepsy syndromes in the above
patients were apparently less active,since chronic med-
ication was not required.Therefore data on active epilep-
sies without AED intake that would answer the question
of epilepsy-specific teratogenicity do not exist,at least
not in countries where sufficient epidemiological studies
on the topic have been performed.
Whether or not children of fathers with epilepsy who are
on AEDs have an increased teratogenic risk is a matter
of controversy.
106,117 The available data do not allow to
claim such an elevated risk unequivocally.An indepen-
dent impact of AEDs is probable,since the risk of mal-
formations is also higher in children of mothers who
were on AEDS for reasons other than epilepsy.
108
Risk in women with epilepsy taking AEDs
In women with epilepsy on AED therapy the teratogenic
risk for major congenital malformations was reported to
range between 4% and approximately 14%.
69,108,109,118,119
The ongoing pregnancy registries report incidence rates
of 3.7% in Taiwan,
120 4.2% in the UK registry,
103 and 6.4%
in Germany.
96 Since association between the risk of mal-
formations and the amount of individual serum peak
concentrations has been suggested,multiple dosing,espe-
cially in the case of VPA,should be considered.
121
Minor congenital malformations such as minor craniofa-
cial abnormalities,epicanthus,or hypertelorism are rela-
tively common in children of women with epilepsy and
treatment with AEDs.However,it is almost impossible
to assess precisely the impact of AEDs.It is apparent that
these abnormalities are not drug-specific as was previ-
ously assumed, and that they are observed under the
influence of each of the classical AEDs.
71,122,123,124 Reliable
data on new AEDs are not yet available.A realistic esti-
mate suggests that minor abnormalities are twice as fre-
quent as in the general population (28% versus 14%).
125
Combinations of AEDs
Polytherapy is a risk factor for congenital malformations,
including new AEDs.
81,96,103,108,113,115 In the UK pregnancy
registry, major congenital malformations occurred in
6.0% of children of mothers on polytherapy as opposed
to a 3.7% incidence in patients on monotherapy (P=0.01)
and 3.5% in women with epilepsy who were not taking
AEDs.
103 Others described a higher incidence in
monotherapy as compared with children of healthy con-
trols or children of mothers with epilepsy but without
AED intake.
108 Combinations with VPA carried a higher
risk for malformations than other combinations.
103The
combination of VPA and LTG which is commonly used
96
was associated with a higher risk of major congenital
malformations than the monotherapy with VPA
126 or any
other combination with LTG.
81 If the AED treatment
prior to pregnancy is changed from VPA to LTG for
safety reasons,one should advise the patient about the
dangers of falling pregnant while the combination is still
taken.
Classical AEDs
The most important finding concerning teratogenicity
that helped to raise awareness in the epilepsy community
was the description of neural tube defects under the
influence of VPA.
127 Neural tube defects develop between
the 17th and the 30th day of a pregnancy.
128The risk of
neural tube defects with VPA is reported to range
between 1% and 2%, with maximum figures of 5.4%
during monotherapy.
71,122,129 In the present interim analy-
sis of the German EURAP study,no neural tube defect
with VPA monotherapy whas been observed.
96
Major congenital malformations with VPA monotherapy
occur in 6.2% to 11.1%.
52,76,103,109,130 Beyond neural tube
defects,skeletal abnormalities,cardiovascular,urogeni-
tal, and cerebral malformations have been typically
reported.
106 Dosages beyond 1000 mg per day appear to
be associated with a markedly elevated risk of malfor-
mations
83,109,131,132 and should therefore be avoided if at all
possible.
The rate of major congenital malformations with CBZ
ranges from 2.2% and 5.7%.
76,103,109 Neural tube defects,
cardiac malformations,hip dislocations,inguinal hernias,
and hypospadia were reported as typical findings.
106
Recent data
103,115,116 indicate that the teratogenic potential
of CBZ is probably not as high as was previously esti-
mated.
110The UK pregnancy registry reports an incidence
of 2.2% of major malformations and thus the lowest rate
of all AEDs.
103 Neural tube defects were reported in 0.5%
to 1.0% in various series.
71,122,133
The incidence rates of congenital major malformations
with PRM,PHT,and PB were 14.3%,3.4% to 9.1% and
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695.1% to 12%, respectively.
109 Typical malformations
under the influence of PHT are cardiac malformations,
craniofacial clefts, and skeletal finger abnormalities.
118
In addition one should be aware of the fetal hydantoin
syndrome that comprises pre- and postnatal growth
retardation, microcephalus, and developmental delay
combined with the abovementioned malformations.
106
Typical malformations with PB therapy are cardiac mal-
formations and craniofacial clefts.
106 The German
EURAP interim report does not mention major mal-
formations with PRM and PB and one cardiac abnor-
mality with PHT.
96 Clefts were also described with ESM
therapy,
106 which was often given as an add-on AED.
Animal studies emphasize the prenatal toxic effects of
the drug.
134
New AEDs
The teratogenic effects of new AEDs are difficult to
assess. In almost all instances the data do not allow
unequivocal conclusions.Animal studies that are usually
performed using extensive dosages and that indicated
teratogenic effects from LEV,TPM,OXC,and VGB but
not from FBM,GPB,LTG and TGB
100 do not necessarily
help to estimate the normal risk in humans.The only new
AED that has been extensively studied in humans is
LTG.According to the Lamotrigine Pregnancy Registry,
the malformation rate was 2.9% and was therefore com-
parable to the spontaneous rate in the healthy popula-
tion.
82 Major malformations with LTG monotherapy
were not described in the ongoing EURAP registries of
Pharmacological aspects
70
Before pregnancy
• Information about genetic risks
• Check the necessity of continuing AED treatment
• Change to monotherapy without VPA if ever possible, data for CBZ and LTG are relatively favorable
• Initiation of folic acid, 0.8 mg per day, if enzyme-inducing AEDs are taken: 5 mg per day
• Discuss additional teratogenic factors such as smoking, drugs, alcohol
First trimester
• Continuation of AED treatment, even in the case of unplanned or unexpected pregnancy.
• Continuation of folic acid. If folic acid was not taken, it should be initiated prior to the 28
th day of pregnancy and continued until the end
of the first trimester
• Assessment of serum concentrations of AEDs
Second trimester
• Prenatal diagnostics (ultrasound, amniocentesis, etc)
• Assessment of serum concentrations of AEDs once per trimester, during treatment with LTG and OXC once per month
Third trimester
• Assessment of serum concentrations of AEDs once per trimester, during treatment with LTG and OXC once per month
Delivery
• Consideration of caesarean section in case of increasing or drug-resistant seizure frequency
• Consideration of temporary additional treatment with low-dose benzodiazepines, especially in case of prolonged delivery
• Caution with hyperventilation
Postnatally
• Application of vitamin K to the newborn
• Extensive search for malformations of the newborn
• Assessment of sedation or sucking weakness of the newborn. Consideration of assessment of AED serum concentration in the child. 
Decision on continuation of breastfeeding
• Dose reduction in case of intoxication signs in the mother (if the AED dosage was increased during the pregnancy). Assessment of AED
serum concentration and dose adaptation if necessary
• No initiation of other AEDs during breastfeeding period (danger of side effects in the child)
• Caution with sleep deprivation, especially in case of idiopathic generalized epilepsy syndromes. The responsibility of the partner should 
be emphasized.
Table II. Recommendations during pregnancy.
24 AED, antiepileptic drug; VPA, valproic acid; LTG, lamotrigine; OXC, oxcarbazepineAustralia or Germany.
96,132The UK Pregnancy Registry
reported a possible dose-dependency with a rate of mal-
formations with LTG dosages above 200 mg that were
approximately in the range of 600 to 1000 mg VPA.
103
This was not confirmed by the reanalysis of the data of
the Lamotrigine Pregnancy Registry.
135 Finally,orofacial
clefts were reported in a few cases,
83 but were not identi-
fied as a convincing drug-specific event in the ongoing
registries.
81,82,96,103,132Thus,the teratogenic risk of monother-
apies with LTG appears to be moderate.More reliable
data on other new AEDs are urgently needed.
Folic acid prophylaxis 
Several studies have shown that folic acid or combina-
tions of vitamins including folic acid were useful to
reduce the risk of neural tube defects in pregnancies of
women with a genetically elevated risk of having a child
with a neural tube defect,and in women during their first
pregnancy,
136,137,138 so that folic acid prophylaxis is gener-
ally recommended if pregnancies are planned. It is
tempting to speculate that women with epilepsy who
have an elevated risk of malformations with AED intake
might benefit even more from folic acid prophylaxis.
However,this hypothesis,though convincing,has not yet
been proven by confirmatory studies.
118 In two patients
on VPA,folic acid did not prevent neural tube defects.
138
Recommendations usually suggest high dosages such as
5 mg per day to overcome the theoretical drawback of
enzyme-inducing AEDs.
24,49,100
A summary of the recommended strategies to reduce the
teratogenic risk in women with epilepsy is shown in Table
II.
Impact of AEDs on further development 
Data on the impact of AEDs on the further development
of children of women with epilepsy are controversial,
100
if variables such as APGAR score, the risk of mental
retardation,behavioral disorders,and the development
of verbal skills are considered.
106,107,122,123 Reports of a
higher risk of cognitive deficits in children whose moth-
ers were on combinations of AEDs compared with
monotherapies
140 may be influenced by a methodological
bias,since the epilepsy syndromes in the former group
may have been more active and more difficult to treat.
However,data on the possibility that children of moth-
ers who took VPA during pregnancy may have a higher
risk of developing cognitive deficits, would rely on a
methodologically convincing study, and this certainly
requires further investigation.
141 Similar suggestions con-
cerning children of mothers who were on CBZ treat-
ment
71,123 have not been confirmed.
142 Other AEDS have
not yet been sufficiently investigated concerning this
important question.
Conclusion
More recently, increasing interest in the influence of
epilepsies themselves and antiepileptic drugs on several
aspects of fertility, pregnancy, teratogenicity, and the
development of the newborn have led to a considerably
improved knowledge about these clinically most relevant
issues.Still,a lot of questions remain to be answered.One
may expect that at least some of these problems will be
partially solved by currently ongoing international preg-
nancy surveys. ❏
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Embarazo, epilepsia y anticonvulsivantes
La mayoría de los trastornos epilépticos no son
autolimitados a lo largo del tiempo, y por lo tanto
requieren de un tratamiento de larga duración y a
menudo de por vida con fármacos antiepilépticos
(FAE). En las mujeres con epilepsia constituyen
temas cruciales la influencia de la enfermedad en
la posibilidad que ocurra el embarazo y en el curso
de éste, como también el potencial impacto del
tratamiento con FAE en la madre y en el niño. 
Esta revisión aborda el conocimiento de relevancia
clínica relacionado con el impacto de la enferme-
dad y del tratamiento con FAE en la fertilidad, el
embarazo, el parto, el período del postparto y la
teratogeneidad. Algunos de los nuevos FAE pare-
cen tener un perfil favorable debido a la falta de
interacciones clínicamente relevantes y a prome-
tedores perfiles teratogénicos. Sin embargo, el
hallazgo de una disminución en la concentración
sérica de lamotrigina durante la anticoncepción
hormonal y el embarazo es un ejemplo ilustrador,
que demuestra que se requieren con urgencia
resultados de los estudios que se están realizando
para investigar diversas preguntas aun no respon-
didas. Algunas investigaciones multinacionales
prospectivas que están desarrollándose en la actua-
lidad deberían aportar información esencial en
esta área.   
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La majorité des troubles épileptiques ne régressent
pas seuls au cours du temps, et nécessitent donc un
traitement antiépileptique de longue durée et par-
fois même à vie. Chez les femmes épileptiques, l’in-
fluence de leur maladie sur la possibilité ou le
cours d’une grossesse, ainsi que l’impact éventuel
du traitement antiépileptique sur la mère et l’en-
fant, sont des questions importantes.
Cet article s’attache aux connaissances clinique-
ment pertinentes concernant l’influence de la
maladie elle-même et du traitement antiépilep-
tique sur la fertilité, la grossesse, la délivrance, le
post-partum et la tératogénicité. Certains nou-
veaux traitements semblent posséder des caracté-
ristiques favorables grâce à l’absence d’interactions
cliniquement significatives et à un profil térato-
gène prometteur. Cependant, la découverte d’une
diminution des concentrations sériques de lamo-
trigine pendant la contraception hormonale et la
grossesse est instructive et montre qu’il faut abso-
lument de nouvelles études pour répondre aux
questions non encore élucidées. Plusieurs études
multinationales prospectives sont actuellement en
cours et devraient permettre de compléter nos
connaissances dans ce contexte.Pregnancy,epilepsy,and AEDs - Steinhoff Dialogues in Clinical Neuroscience - Vol 10 . No.1 . 2008
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